Business
Appointment of Joint Broker
Appointment of Joint Broker.
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 2885Y Shield Therapeutics PLC 08 May 2019 \n\nShield Therapeutics plc\n(\"Shield\" or the \"Group\")\n \nAppointment of Joint Broker\n \nLondon, UK, 8 May 2019: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru®, announces the appointment of finnCap Ltd as its joint broker with immediate effect.\n \n- Ends -\n \nFor further information please contact:\n \n\n\n\nShield Therapeutics plc\n\n\nwww.shieldtherapeutics.com \n\n\n\n\n Carl Sterritt, Chief Executive Officer\n\n\n+44 (0)20 71868500\n\n\n\n\nTim Watts, Chief Financial Officer\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNominated Advisor and Joint Broker\n\n\n\n\n\n\n\nPeel Hunt LLP\n\n\n\n\n\n\n\nJames Steel/Dr Christopher Golden \n\n\n+44 (0)20 74188900\n\n\n\n\n\n\n\n\n\n\n\n\nJoint Broker\n\n\n\n\n\n\n\nfinnCap Ltd\n\n\n +44 (0)20 72200500\n\n\n\n\nGeoff Nash /Matt Radley/ Alice Lane \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFinancial PR & IR Advisor\n\n\n\n\n\n\n\nWalbrook PR\n\n\n+44 (0)20 79338780 or [email protected]\n\n\n\n\nPaul McManus / Helen Cresswell\n\n\n+44 (0)7980 541893 / +44 (0)7841 917679\n\n\n\n \nAbout Shield Therapeutics plc\nShield is a de-risked, commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to h...